Latest:
Practice Patterns and Real Use of Epcoritamab and Glofitamab
A panel of experts discuss the role of odronextamab.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Leonard Saltz, MD
Latest:
Dr. Saltz Discusses FOLFIRINOX in Colorectal Cancer
Leonard Saltz, MD, executive director for Clinical Value & Sustainability, head, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, discusses the option of FOLFIRINOX for the treatment of patients with metastatic colorectal cancer.
Leonie de Best, MSc2
Latest:
Leonie de Best on Validation of EMC92/SKY92 Signature in Myeloma
Leonie de Best, MSc2, chief operating officer, SkylineDX, discusses the HOVON-87/NMSG-18 study, which demonstrated the validation of the EMC92/SKY92 signature for elderly patients with newly diagnosed multiple myeloma.
Leora Horn, MD
Latest:
Dr. Horn on Updated IMpower133 Data in Small Cell Lung Cancer
Leora Horn, MD, MSc, discusses data from an updated analysis of the phase 3 IMpower133 trial, which examined the first-line combination of atezolizumab (Tecentriq), carboplatin, and etoposide in small cell lung cancer.
Leslie M. Randall, MD
Latest:
Future Directions in the Treatment of Recurrent or Metastatic Cervical Cancer
The panel closes their discussion by highlighting challenges in the treatment of cervical cancer, emphasizing the need for more focus on clinical trials and therapies, as well as addressing disparities in cancer care, particularly for patients of color.
Linda A. Malek, Lauren Mack
Latest:
Internal Investigations May be Open to Court and Government Agency Scrutiny
Given a handful of recent cases, and a recent update to the CMS Voluntary Self-Referral Disclosure Protocol, it appears that the federal government may be using the existence of these audits as a means for demonstrating that the provider "knew or should have known" that fraud occurred.